Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIndivior PLC Ordinary Shares

Indivior PLC Ordinary Shares

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-10T15:00:13.154640Z
Market Cap
2492.01M
P/E
462.00

Momentum Score

…

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
14.38
Low
26.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Indivior PLC is a specialty pharmaceutical company focused on development, manufacture and commercialization of treatments for opioid use disorder and related addictions, primarily marketed buprenorphine-based therapies. Long-term growth drivers include persistent demand for addiction treatment, new formulation and depot-product development, and geographic expansion, which may benefit from an established commercial footprint and recurring revenue from branded products.
Key investment risks include exposure to generic competition for core products, ongoing regulatory and legal scrutiny, revenue concentration in a small product portfolio and pricing or reimbursement pressure that could materially affect results.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
26.74
Dividend Yield
-
Revenue TTM
1124.00M
Revenue Per Share
8.20
Gross Profit TTM
742.00M
Debt / Equity
-
ROE
12.20%
Net Debt
-
ROCE
32.67%
Diluted EPS TTM
0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -95.00M 190.00M -173.00M 180.00M
Net income -53.00M 205.00M -148.00M 134.00M
Selling general administrative 763.00M 418.00M 649.00M 395.00M
Gross profit 742.00M 664.00M 550.00M 645.00M
Reconciled depreciation 21.00M 22.00M 26.00M 28.00M
Ebit 212.00M 187.00M 88.00M 202.00M
Ebitda -45.00M 239.00M -121.00M 230.00M
Operating income -91.00M 181.00M -156.00M 178.00M
Other operating expenses -3.00M -3.00M -3.00M -3.00M
Interest expense 29.00M 27.00M 26.00M 22.00M
Tax provision -42.00M -15.00M -25.00M 46.00M
Interest income 19.00M 4.00M 9.00M 24.00M
Net interest income -10.00M -23.00M -17.00M 2.00M
Income tax expense -42.00M -15.00M -25.00M 46.00M
Total revenue 901.00M 791.00M 647.00M 785.00M
Total operating expenses 992.00M 610.00M 803.00M 607.00M
Cost of revenue 159.00M 127.00M 97.00M 140.00M
Net income from continuing ops -53.00M 205.00M -148.00M 134.00M
Net income applicable to common shares -53.00M 205.00M -148.00M 134.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1954.00M 1769.00M 1832.00M 1531.00M 1652.00M
Intangible assets 232.00M 70.00M 82.00M 62.00M 72.00M
Other current assets 434.00M 13.00M 14.00M 33.00M 12.00M
Total liab 1954.00M 1718.00M 1629.00M 1449.00M 1443.00M
Total stockholder equity 0.00M 51.00M 203.00M 82.00M 209.00M
Other current liab 125.00M 391.00M 73.00M 459.00M 570.00M
Common stock - 68.00M 70.00M 73.00M 73.00M
Capital stock 68.00M 68.00M 70.00M 73.00M 73.00M
Retained earnings 1244.00M 1303.00M 1438.00M 1311.00M 1449.00M
Other liab - 433.00M 550.00M 577.00M 417.00M
Good will 5.00M - - - -
Other assets - 257.00M 211.00M 179.00M 113.00M
Cash 316.00M 774.00M 1102.00M 858.00M 1060.00M
Total current liabilities 1305.00M 1019.00M 804.00M 599.00M 742.00M
Short long term debt 3.00M 3.00M 3.00M 4.00M 4.00M
Other stockholder equity - -1328.00M -1312.00M -1308.00M -1318.00M
Property plant equipment - 85.00M 95.00M 103.00M 107.00M
Total current assets 1263.00M 1259.00M 1444.00M 1187.00M 1360.00M
Net tangible assets - -19.00M 121.00M 20.00M 137.00M
Short term investments 94.00M 119.00M - - -
Net receivables 254.00M 225.00M 215.00M 186.00M 192.00M
Long term debt 236.00M 237.00M 239.00M 230.00M 233.00M
Inventory 142.00M 114.00M 95.00M 93.00M 73.00M
Accounts payable 39.00M 36.00M 137.00M 20.00M 39.00M
Non currrent assets other 9.00M 18.00M 84.00M 82.00M 50.00M
Non current assets total 691.00M 510.00M 388.00M 344.00M 292.00M
Capital lease obligations 43.00M 37.00M 44.00M 51.00M 56.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -218.00M -218.00M -218.00M -218.00M
Change to liabilities -98.00M 201.00M -103.00M -101.00M
Total cashflows from investing activities -223.00M -14.00M -4.00M -2.00M
Net borrowings -12.00M 6.00M -11.00M -13.00M
Total cash from financing activities -100.00M -94.00M -10.00M -13.00M
Change to operating activities 269.00M 269.00M 85.00M -64.00M
Net income -53.00M 205.00M -148.00M 134.00M
Change in cash -328.00M 244.00M -202.00M 136.00M
Begin period cash flow 1102.00M 858.00M 1060.00M 924.00M
End period cash flow 774.00M 1102.00M 858.00M 1060.00M
Total cash from operating activities -4.00M 353.00M -193.00M 151.00M
Issuance of capital stock 2.00M 1.00M 1.00M 0.00M
Depreciation 19.00M 19.00M 21.00M 20.00M
Other cashflows from investing activities - - - 1.00M
Change to inventory -25.00M -3.00M -16.00M 7.00M
Change to account receivables -21.00M -25.00M 15.00M 79.00M
Sale purchase of stock -90.00M -101.00M - -
Change to netincome -97.00M -47.00M -52.00M 68.00M
Capital expenditures 5.00M 4.00M 4.00M 7.00M
Change in working capital 125.00M 173.00M -19.00M -79.00M
Stock based compensation 16.00M 11.00M 8.00M 3.00M
Free cash flow -10.00M 319.00M -197.00M 144.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR		 -0.14
0.42%		 33.57 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 0.40
0.24%		 170.10 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.31
1.47%		 20.78 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Indivior PLC Ordinary Shares

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235

804 379 1090

https://www.indivior.com

1000

Name Title Year Born
Mr. Mark Crossley CEO & Executive Director NA
Mr. Ryan Preblick CFO & Executive Director NA
Dr. Christian Heidbreder Chief Scientific Officer NA
Mr. Jason Thompson Vice President of Investor Relations NA
Ms. Cynthia Cetani Chief Integrity & Compliance Officer NA
Mr. Jeffrey W. Burris Chief Legal Officer 1972
Mr. Jon Fogle Chief Human Resources Officer NA
Mr. Richard Simkin Chief Commercial Officer NA
Mr. Hillel West Chief Manufacturing & Supply Officer NA
Mr. Vishal Kalia SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

No data available
No data available

Equity Sectors*

  • Basic Materials

    -2.54%

  • Communication Services

    +0.09%

  • Consumer Cyclical

    -0.16%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.11%

  • Financial Services

    +0.15%

  • Healthcare

    -0.77%

  • Industrials

    -0.93%

  • Real Estate

    -0.17%

  • Technology

    -0.09%

  • Utilities

    -0.67%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…